Key regions: Germany, South Korea, France, United States, United Kingdom
Romania, a country located in Southeast Europe, has been experiencing a growing demand for anti-coagulants in recent years.
Customer preferences: Patients in Romania are increasingly seeking out anti-coagulants as a means of preventing and treating blood clots. This trend is in line with global market trends, as the prevalence of cardiovascular diseases continues to rise. Additionally, the aging population in Romania has contributed to the growth of the anti-coagulants market, as the elderly are more susceptible to blood clots and related conditions.
Trends in the market: One of the main trends in the anti-coagulants market in Romania is the increasing use of direct oral anticoagulants (DOACs) over traditional vitamin K antagonists (VKAs). DOACs have been shown to be more effective and easier to use than VKAs, leading to a shift in preference among both patients and healthcare providers. Furthermore, the growing availability of DOACs in Romania has contributed to their increasing use. Another trend in the market is the development of new oral anticoagulants, which are expected to further drive growth in the market.
Local special circumstances: One factor that has contributed to the growth of the anti-coagulants market in Romania is the country's healthcare system. The Romanian government has made efforts to improve access to healthcare services, including the availability of medications such as anti-coagulants. Additionally, the increasing prevalence of cardiovascular diseases in Romania has led to a greater focus on preventative care and the use of medications such as anti-coagulants.
Underlying macroeconomic factors: The Romanian economy has been growing steadily in recent years, which has contributed to the growth of the healthcare sector. Additionally, the country's membership in the European Union has led to increased investment in the healthcare industry. These macroeconomic factors have created a favorable environment for the growth of the anti-coagulants market in Romania.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
